Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 May 19;2(2):67-71.
doi: 10.1007/s13317-011-0020-1. eCollection 2011 Nov.

Assessment of a combination screening assay for celiac disease

Brunetta Porcelli  1 , Fabio Ferretti  2 , Carla Vindigni  3 , Carlo Scapellaato  4 , Lucia Terzuoli  1
Affiliations

Assessment of a combination screening assay for celiac disease

Brunetta Porcelli et al. Auto Immun Highlights. .

Erratum in

Abstract

Purpose: A serological screening assay for celiac disease (CD), designed to simultaneously detect IgA and IgG anti-tissue transglutaminase (a-tTG) and IgA and IgG deamidated gliadin peptide antibodies (a-DGP), was recently developed. In this study, we establish the performance of this assay.

Methods: We enrolled 41 CD patients and 18 CD patients on gluten-free diets. The diagnosis of CD was based on histological and serological criteria, including concomitant positive serology tests (a-tTG, IgA anti-endomysial antibodies). As control population, we enrolled 169 subjects: 145 disease controls and 24 blood donors. In all cases, serum samples were tested for: IgA a-tTG, IgG a-tTG, IgA a-DGP, IgG a-DGP, IgA anti-endomysial antibodies (EMA), IgA and IgG for a-tTG and a-DGP in a single assay.

Results: The new test, QUANTA Lite (™) h-tTG/DGP Screen, detects all IgA and IgG antibodies against atTG and a-DGP present in a sample. In our study, the test showed 100% sensitivity and 91.12% specificity.

Conclusions: This study showed additional value of the new h-tTG/DGP Screen assay, which proved superior to more conventional assays and can be considered the best initial test for CD. Further studies are necessary to determine whether combination of h-tTG/DGP Screen with IgA a-tTG or IgA a-DGP can be used to obviate the need for duodenal biopsy in high- and low-risk populations.

Keywords: Anti-tissue transglutaminase antibodies; Celiac disease; Deamidated gliadin peptide antibodies; Diagnosis; Serological screening assay.

PubMed Disclaimer

References

    1. Fasano A, Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology. 2001;120:636–651. doi: 10.1053/gast.2001.22123. - DOI - PubMed
    1. Craig D, Robins G, Howdle PD. Advances in CD. Curr Opin Gastroenterol. 2007;23:142–148. - PubMed
    1. Tonutti E, Visentini D, Bizzaro N, Caradonna M, Cerni L, Villalta D, Tozzoli R. The role of antitissue transglutaminase assay for the diagnosis and monitoring of coeliac disease: a French-Italian multicentre study. J Clin Pathol. 2003;56:389–393. doi: 10.1136/jcp.56.5.389. - DOI - PMC - PubMed
    1. NIH Consensus Development Conference on Celiac Disease, Bethesda (2004) http://www.consensus.nih.gov/cons/118/118cdc_intro.htm - PubMed
    1. Hill ID. What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? Gastroenterology. 2005;128:S25–S32. doi: 10.1053/j.gastro.2005.02.012. - DOI - PubMed